Nuveen Asset Management LLC Purchases 8,193 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Nuveen Asset Management LLC increased its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 4.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 212,351 shares of the company's stock after buying an additional 8,193 shares during the period. Nuveen Asset Management LLC owned 0.37% of Harmony Biosciences worth $7,307,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the company. Deep Track Capital LP acquired a new stake in Harmony Biosciences in the 4th quarter valued at about $49,894,000. Vanguard Group Inc. raised its stake in Harmony Biosciences by 36.4% in the 4th quarter. Vanguard Group Inc. now owns 4,733,609 shares of the company's stock valued at $162,883,000 after acquiring an additional 1,262,362 shares during the period. Marshall Wace LLP lifted its holdings in Harmony Biosciences by 165.2% during the 4th quarter. Marshall Wace LLP now owns 929,744 shares of the company's stock valued at $31,992,000 after purchasing an additional 579,103 shares during the last quarter. Norges Bank bought a new position in Harmony Biosciences during the fourth quarter worth $16,118,000. Finally, Invesco Ltd. increased its holdings in shares of Harmony Biosciences by 173.9% in the fourth quarter. Invesco Ltd. now owns 449,180 shares of the company's stock valued at $15,456,000 after purchasing an additional 285,156 shares during the last quarter. Institutional investors and hedge funds own 86.23% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. UBS Group reduced their target price on shares of Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating for the company in a report on Monday, April 28th. Cantor Fitzgerald upgraded Harmony Biosciences to a "strong-buy" rating in a research note on Tuesday, May 13th. Mizuho upped their price objective on Harmony Biosciences from $44.00 to $48.00 and gave the company an "outperform" rating in a report on Thursday, May 15th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Harmony Biosciences in a research report on Tuesday, February 11th. They issued a "buy" rating and a $55.00 target price for the company. Finally, Oppenheimer assumed coverage on shares of Harmony Biosciences in a research report on Monday. They set an "outperform" rating and a $61.00 price target on the stock. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $53.00.

Harmony Biosciences Price Performance

Shares of NASDAQ HRMY traded down $0.25 during trading hours on Tuesday, hitting $35.31. 835,807 shares of the stock were exchanged, compared to its average volume of 611,436. The company's fifty day simple moving average is $31.63 and its two-hundred day simple moving average is $34.01. The company has a market cap of $2.03 billion, a PE ratio of 16.73, a price-to-earnings-growth ratio of 0.47 and a beta of 0.87. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. Harmony Biosciences Holdings, Inc. has a 1-year low of $26.47 and a 1-year high of $41.61.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.19. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The company had revenue of $184.73 million for the quarter, compared to analyst estimates of $184.26 million. During the same quarter last year, the company posted $0.67 EPS. The company's revenue for the quarter was up 19.5% compared to the same quarter last year. On average, sell-side analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.